Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$36.45 - $47.7 $39.3 Million - $51.4 Million
1,077,321 New
1,077,321 $51.3 Million
Q2 2023

Aug 14, 2023

SELL
$34.73 - $43.33 $2.7 Million - $3.36 Million
-77,616 Reduced 38.15%
125,850 $5.16 Million
Q1 2023

May 15, 2023

BUY
$33.58 - $41.2 $6.83 Million - $8.38 Million
203,466 New
203,466 $7.27 Million
Q2 2022

Aug 15, 2022

BUY
$31.71 - $43.0 $4.93 Million - $6.69 Million
155,533 New
155,533 $5.76 Million
Q1 2022

May 16, 2022

SELL
$29.88 - $37.04 $5.77 Million - $7.15 Million
-193,120 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$25.61 - $35.1 $1.31 Million - $1.79 Million
51,105 Added 35.99%
193,120 $5.88 Million
Q3 2021

Nov 15, 2021

SELL
$33.54 - $40.55 $4.07 Million - $4.92 Million
-121,271 Reduced 46.06%
142,015 $4.76 Million
Q2 2021

Aug 16, 2021

BUY
$34.54 - $47.25 $9.09 Million - $12.4 Million
263,286 New
263,286 $10.5 Million
Q1 2021

May 17, 2021

SELL
$42.51 - $63.78 $1.91 Million - $2.86 Million
-44,848 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$45.3 - $60.27 $2.03 Million - $2.7 Million
44,848 New
44,848 $2.54 Million
Q4 2019

Feb 14, 2020

SELL
$53.85 - $65.27 $13.6 Million - $16.5 Million
-253,265 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$59.06 - $72.15 $15 Million - $18.3 Million
253,265 New
253,265 $15.2 Million
Q1 2018

May 15, 2018

SELL
$44.08 - $55.05 $551,000 - $688,125
-12,500 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$50.3 - $64.39 $372,220 - $476,486
7,400 Added 145.1%
12,500 $629,000
Q3 2017

Nov 14, 2017

BUY
$45.56 - $59.57 $232,356 - $303,807
5,100
5,100 $259,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.35B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.